ASTELLAS PHARMA
🇯🇵Japan
- Country
- 🇯🇵Japan
- Ownership
- -
- Established
- 2005-01-01
- Employees
- -
- Market Cap
- $22.5B
- Website
- https://www.astellas.com/
Drug-drug Interaction Study With ASP1941 and Glimepiride
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 52
- Registration Number
- NCT01302158
Mass Balance Study of ASP1941
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2011-02-23
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 6
- Registration Number
- NCT01302132
Renal Impairment Study With ASP1941
- First Posted Date
- 2011-02-23
- Last Posted Date
- 2017-08-22
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 40
- Registration Number
- NCT01302028
A Study to Evaluate the Possible Effects of Taking Mirabegron While Taking a Contraceptive Pill
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 30
- Registration Number
- NCT01297179
A Clinical Study to Assess the Effect on Pharmacokinetics of Dosing Mirabegron (YM178) and Solifenacin Simultaneously
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2011-02-16
- Last Posted Date
- 2013-07-29
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 41
- Registration Number
- NCT01297192
First in Men Study of Single Oral Doses of ASP1941 in Healthy Subjects
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2011-02-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 76
- Registration Number
- NCT01288885
Multiple Dose Escalating Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP1941
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2011-02-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 48
- Registration Number
- NCT01288898
A Study of Enzalutamide Versus Bicalutamide in Castrate Men With Metastatic Prostate Cancer
- First Posted Date
- 2011-02-03
- Last Posted Date
- 2024-12-06
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 375
- Registration Number
- NCT01288911
- Locations
- 🇷🇴
Site RO3042, Bucharest, RO, Romania
🇷🇴Site RO3039, Bucharest, RO, Romania
🇷🇴Site RO3035, Bucharest, Romania
A Study to Evaluate How Mirabegron Enters and Leaves the Bloodstream According to Age and Sex
Phase 1
Completed
- Conditions
- First Posted Date
- 2011-01-28
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 75
- Registration Number
- NCT01285596
A Study to Assess Intraocular Pressure and Ocular Safety of the Beta-3 Agonist Mirabegron in Research Subjects
- First Posted Date
- 2011-01-27
- Last Posted Date
- 2013-12-11
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 321
- Registration Number
- NCT01284309
- Locations
- 🇺🇸
Celerion, Lincoln, Nebraska, United States
© Copyright 2024. All Rights Reserved by MedPath